Cost minimisation of RSV prevention with palivizumab
نویسندگان
چکیده
منابع مشابه
AAP Issues Updated Guidance on Palivizumab Prophylaxis for RSV Infection.
Volume 90, Number 12 www.aafp.org/afp American Family Physician 867 The American Academy of Pediatrics (AAP) Committee on Infectious Diseases has updated its guidance on the use of palivizumab (Synagis) prophylaxis in infants and children at increased risk of respiratory syncytial virus (RSV) infection. Because the palivizumab package labeling does not include a definition of high-risk children...
متن کاملRevised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Pr...
متن کاملThe Medicaid Cost of Palivizumab
1. Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2013–14 influenza season. MMWR Recomm Rep 2013; 62:1–43. 2. Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Inf...
متن کاملThe use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia.
Palivizumab is a humanized monoclonal antibody used to decrease the threat of respiratory syncytial virus (RSV) infection among children at high risk. There are no standard guidelines due to conflicting data on palivizumab's use in the treatment of RSV lower respiratory tract infections. Intravenous (IV) palivizumab was shown to be well tolerated and associated with decreased mortality in high-...
متن کاملThe Use of Intravenous Palivizumab for Treatment of Persistent RSV Infection in Children With Leukemia abstract
Palivizumab is a humanized monoclonal antibody used to decrease the threat of respiratory syncytial virus (RSV) infection among children at high risk. There are no standard guidelines due to conflicting data on palivizumab’s use in the treatment of RSV lower respiratory tract infections. Intravenous (IV) palivizumab was shown to be well tolerated and associated with decreased mortality in high-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Disease in Childhood
سال: 2006
ISSN: 0003-9888,1468-2044
DOI: 10.1136/adc.2005.093484